Kuznicki Law is investigating the proposed sale of Poseida Therapeutics, Inc. (NasdaqGS: PSTX) to Roche Holdings, Inc. Under the terms of the proposed transaction, shareholders of Poseida will receive $9.00 in cash plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $4.00 per share in cash (upon achievement of specific milestones), for each share of Poseida that they own. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Please note that the transaction is structured as a tender offer, such that time may be of the essence.